Merck & Co., Inc. (MRK)
NYSE: MRK · Real-Time Price · USD
99.70
-0.17 (-0.17%)
Dec 27, 2024, 4:00 PM EST - Market closed
Merck & Co. Revenue
Merck & Co. had revenue of $16.66B in the quarter ending September 30, 2024, with 4.35% growth. This brings the company's revenue in the last twelve months to $63.17B, up 6.51% year-over-year. In the year 2023, Merck & Co. had annual revenue of $60.12B with 1.40% growth.
Revenue (ttm)
$63.17B
Revenue Growth
+6.51%
P/S Ratio
4.00
Revenue / Employee
$877,417
Employees
72,000
Market Cap
252.20B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 60.12B | 832.00M | 1.40% |
| Dec 31, 2022 | 59.28B | 10.58B | 21.72% |
| Dec 31, 2021 | 48.70B | 7.19B | 17.31% |
| Dec 31, 2020 | 41.52B | 2.40B | 6.13% |
| Dec 31, 2019 | 39.12B | -3.17B | -7.50% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 393.90B |
| Johnson & Johnson | 87.70B |
| AbbVie | 55.53B |
| AstraZeneca | 51.21B |
| Novartis AG | 49.94B |
| Thermo Fisher | 42.37B |
| Abbott Laboratories | 41.22B |
| Eli Lilly | 40.86B |
MRK News
- 2 days ago - Top 7 Blue-Chip Stocks With The Best Return Potential Going Into 2025 - Benzinga
- 4 days ago - Merck to discontinue drug for bacterial infection - Reuters
- 4 days ago - Merck: A Low-Hanging Fruit To Pick - Seeking Alpha
- 5 days ago - Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More - Benzinga
- 7 days ago - Merck Closes Exclusive Global License Agreement for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody - Business Wire
- 8 days ago - Stock Of The Day: Where Does The Merck Downtrend End? - Benzinga
- 8 days ago - Merck: Healthcare Pharma Giant: 3.2% Yield, 9.3% 5-Year Dividend Growth, Buy Time - Seeking Alpha
- 8 days ago - Merck's HIV treatment meets main goal of two late-stage studies - Reuters